{"id":10238,"date":"2025-09-12T18:39:30","date_gmt":"2025-09-12T16:39:30","guid":{"rendered":"https:\/\/aliber.org\/web\/?p=10238"},"modified":"2025-09-12T18:39:30","modified_gmt":"2025-09-12T16:39:30","slug":"acopel-comparte-foro-sobre-innovacion-farmaceutica-impulsa-nuevas-oportunidades-para-colombia","status":"publish","type":"post","link":"https:\/\/aliber.org\/web\/2025\/09\/12\/acopel-comparte-foro-sobre-innovacion-farmaceutica-impulsa-nuevas-oportunidades-para-colombia\/","title":{"rendered":"ACOPEL comparte: Foro sobre innovaci\u00f3n farmac\u00e9utica impulsa nuevas oportunidades para Colombia"},"content":{"rendered":"<p>El pasado 11 de septiembre, se destac\u00f3 la participaci\u00f3n de Luz Victoria Salazar, directora y presidenta del Observatorio Interinstitucional de Enfermedades Hu\u00e9rfanas, en el foro <strong>\u201cInnovaci\u00f3n farmac\u00e9utica: m\u00e1s oportunidades para Colombia\u201d<\/strong>, organizado por <em>Foros Semana<\/em> en la Universidad EAN, en Bogot\u00e1.<\/p>\n<p>Este encuentro reuni\u00f3 a l\u00edderes de la industria, autoridades, expertos y representantes de pacientes para debatir c\u00f3mo la innovaci\u00f3n, la producci\u00f3n nacional y la regulaci\u00f3n pueden impulsar el desarrollo, la competitividad y el bienestar dentro del sistema de salud colombiano.<\/p>\n<p>La participaci\u00f3n de ACOPEL en escenarios como este reafirma el compromiso de incidir en pol\u00edticas p\u00fablicas, visibilizar la voz de los pacientes y construir puentes entre los diferentes actores del sector salud, con el fin de garantizar un futuro m\u00e1s justo, innovador y sostenible para quienes conviven con enfermedades hu\u00e9rfanas en el pa\u00eds.<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-10243 size-full\" src=\"https:\/\/aliber.org\/web\/wp-content\/uploads\/2025\/09\/a.jpeg\" alt=\"\" width=\"757\" height=\"760\" srcset=\"https:\/\/aliber.org\/web\/wp-content\/uploads\/2025\/09\/a.jpeg 757w, https:\/\/aliber.org\/web\/wp-content\/uploads\/2025\/09\/a-300x300.jpeg 300w, https:\/\/aliber.org\/web\/wp-content\/uploads\/2025\/09\/a-150x150.jpeg 150w, https:\/\/aliber.org\/web\/wp-content\/uploads\/2025\/09\/a-250x250.jpeg 250w, https:\/\/aliber.org\/web\/wp-content\/uploads\/2025\/09\/a-174x174.jpeg 174w, https:\/\/aliber.org\/web\/wp-content\/uploads\/2025\/09\/a-120x120.jpeg 120w\" sizes=\"(max-width: 757px) 100vw, 757px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El pasado 11 de septiembre, se destac\u00f3 la participaci\u00f3n de Luz Victoria Salazar, directora y presidenta del Observatorio Interinstitucional de Enfermedades Hu\u00e9rfanas, en el foro \u201cInnovaci\u00f3n farmac\u00e9utica: m\u00e1s oportunidades para<a href=\"https:\/\/aliber.org\/web\/2025\/09\/12\/acopel-comparte-foro-sobre-innovacion-farmaceutica-impulsa-nuevas-oportunidades-para-colombia\/\">[&#8230;]<\/a><\/p>\n","protected":false},"author":1,"featured_media":10243,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[3,138,7],"tags":[],"class_list":["post-10238","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-eventos","category-noticias","category-socios"],"_links":{"self":[{"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/posts\/10238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/comments?post=10238"}],"version-history":[{"count":1,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/posts\/10238\/revisions"}],"predecessor-version":[{"id":10244,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/posts\/10238\/revisions\/10244"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/media\/10243"}],"wp:attachment":[{"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/media?parent=10238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/categories?post=10238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aliber.org\/web\/wp-json\/wp\/v2\/tags?post=10238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}